Prerpints.org logo
Preprint
Article

This version is not peer-reviewed.

Anti-CD44 Variant 10 Monoclonal Antibody Exerts Antitumor Activity in Mouse Xenograft Models of Oral Squamous Cell Carcinomas

A peer-reviewed article of this preprint also exists.

Submitted:

02 August 2024

Posted:

06 August 2024

You are already at the latest version

Abstract
CD44 regulates cell adhesion, proliferation, survival, and stemness and has been considered a tumor therapy target. CD44 possesses the shortest CD44 standard (CD44s) and a variety of CD44 variant (CD44v) isoforms. Since the expression of CD44v is restricted in epithelial cells and carcinomas compared to CD44s, CD44v has been considered a promising target for monoclonal antibody (mAb) therapy. We previously developed an anti‐CD44v10 mAb, C44Mab-18 (IgM, kappa) to recognize the variant exon 10-encoded region. In the present study, a mouse IgG2a version of C44Mab-18 (C44Mab-18-mG2a) was generated to evaluate the antitumor activities against CD44-positive cells compared with previously established anti-pan CD44 mAb, C44Mab-46-mG2a. C44Mab-18-mG2a exhibited higher reactivity compared with C44Mab-46-mG2a to CD44v3–10-overexpressed CHO-K1 (CHO/CD44v3–10) and oral squamous cell carcinoma cell lines (HSC-2 and SAS) in flow cytometry. C44Mab-18-mG2a exerted a superior antibody‐dependent cellular cytotoxicity (ADCC) against CD44v3–10. In contrast, C44Mab-46-mG2a showed a superior complement‐dependent cytotoxicity (CDC) against CD44v3–10. A similar tendency was observed in ADCC and CDC against HSC-2 and SAS. Furthermore, administering C44Mab-18-mG2a or C44Mab-46-mG2a significantly suppressed CD44v3–10, HSC-2, and SAS xenograft tumor growth compared with the control mouse IgG2a. These results indicate that C44Mab-18-mG2a could be a promising therapeutic regimen for CD44v10-positive tumors.
Keywords: 
CD44 variant 10
;  
monoclonal antibody
;  
ADCC
;  
CDC
;  
oral cancer
;  
antitumor activity
Subject: 
Medicine and Pharmacology  -   Oncology and Oncogenics

1. Introduction

CD44 is involved in the tumor malignant progression through the promotion of tumor cell proliferation, migration, invasiveness, and stemness [1]. The variety of CD44 function is mediated by the alternative splicing of 20 exons [2]. CD44 standard (CD44s), the shortest isoform of CD44, is generated by the first five (1–5) and the last five (16–20) exons and expressed in a broad range of tissues. The central (6–15) exons are alternatively spliced and inserted between the first and last five exons of CD44s. The variant exon-containing CD44 is designated as the CD44 variant (CD44v) isoform [3].
The CD44 ectodomain includes a hyaluronic acid (HA)-binding domain (HABD) [4]. The HABD is present in both CD44s and CD44v isoforms. Upon HA binding, CD44s and CD44v transduce the intracellular signaling through the cytoplasmic domain, which promotes cell migration and proliferation [5]. The variant exons-encoding regions possess a variety of functions. The v3-encoded region can be attached to a heparan sulfate side chain, which recruits heparin-binding growth factors and stimulates the signal transduction through activation of the receptors [6,7]. The v6-encoded region potentiates the MET signaling pathway through the formation of a ternary complex with its ligand, hepatocyte growth factor [8,9]. Moreover, the v8–10-encoded region regulates the intracellular reduced glutathione levels through the promotion of a cystine–glutamate transporter function [10]. These functions are essential for tumor cell proliferation, invasiveness, and survival to oxidative stress [10] and chemotherapeutic drugs [11]. Therefore, CD44 has been considered as an essential target for tumor therapy [4].
Monoclonal antibodies (mAbs) against CD44 have been evaluated in clinical trials [12,13]. RG7356, a humanized anti-pan-CD44 mAb, exhibited the antitumor effect for B cell leukemia but no cytotoxicity on normal B cells [14]. In human chronic lymphocytic leukemia-engrafted mouse model, RG7356 administration resulted in complete clearance of engrafted leukemia cells [14]. In acute myeloid leukemia [15] and advanced CD44-positive solid tumor [16], phase I clinical trials were conducted. Although RG7356 exhibited an acceptable safety profile, the studies were terminated due to the lack of dose-response relationship with RG7356 in both clinical and pharmacodynamic aspects [16].
Since CD44v expression is restricted in epithelial tissue and carcinomas, anti-CD44v mAbs were developed and evaluated in clinical studies. Humanized anti-CD44v6 mAbs (BIWA-4 and BIWA-8) labeled with 186Re showed antitumor efficacy in head and neck squamous cell carcinoma (SCC) xenograft-bearing mice [17]. Moreover, the antibody-drug conjugate (ADC) of BIWA-4, bivatuzumab-mertansine, was developed and evaluated in clinical trials [13]. However, the clinical trials were terminated due to severe toxicity in the skin, probably due to the efficient accumulation of mertansine in the skin [13,18]. Therefore, anti-CD44 mAbs with more potent efficacy and lower toxicity to normal cells are desired.
The Fc region of therapeutic mAb binds to FcγRs on dendritic cells, macrophages, and neutrophils, which influences the adaptive immune responses through antigen presentation and cytokine production [19]. Moreover, the FcγR binding results in the activation of natural killer (NK) cells and macrophages, which mediates antibody-dependent cellular cytotoxicity (ADCC) [19]. The complement-dependent cellular cytotoxicity (CDC) is also considered as an essential effector function in tumor immunotherapy [20]. The Fc region of therapeutic mAb binds to complement C1q, facilitating the assembly of active C1 complex (C1q, C1r, and C1s). The reaction of the complement cascade finally promotes the assembly of the pore-forming membrane attack complex (MAC or C5b–C9) on the tumor cell membrane, which results in the terminal cell lysis [20]. The involvement of CDC in the antitumor effect was first recognized in the treatment of B cell lymphomas by an anti-CD20 mAb, rituximab [21,22]. Furthermore, the cytolytic capacity by complements has been shown in anti-CD38 and CD52 immunotherapies for multiple myeloma and chronic lymphocytic leukemia, respectively [22,23,24]. Moreover, a growing body of evidence suggests that complement plays critical roles in not only tumor cell lysis but also several immunologic functions in antitumor immunity [25,26]. In the immunotherapy against solid tumors, an anti-HER2 bispecific and biparatopic antibody, zanidatamab, exerted more potent CDC against HER2-positive breast cancers compared with clinically approved anti-HER2 mAb, trastuzumab [27].
The Cell-Based Immunization and Screening method is a strategy to obtain mAbs against a membrane protein comprehensively. We immunized mice with the CD44v3–10-overexpressed cells or CD44v3–10 ectodomain and established various anti-CD44 mAbs and determined their epitopes. C44Mab-5 [28] and C44Mab-46 [29] are anti-pan-CD44 mAbs, which have the epitopes within the constant exon 2- and 5-encoded sequences, respectively [30,31,32]. We also established various CD44v-specific mAbs. C44Mab-6 recognizes variant exon 3-encoded sequences and is referred to as anti-CD44v3 mAb [33]. Furthermore, C44Mab-3 (an anti-CD44v5 mAb) [34], C44Mab-9 (an anti-CD44v6 mAb) [35], C44Mab-34 (an anti-CD44v7/8 mAb) [36], C44Mab-1 (an anti-CD44v9 mAb) [37], and C44Mab-18 (an anti-CD44v10 mAb) [38] were established. C44Mab-108 is an anti-CD44v4 mAb, established by peptide immunization [39]. These mAbs cover almost all variant exons and are applicable to flow cytometry, western blotting, and immunohistochemistry.
In this study, we produced an IgG2a-type C44Mab-18 (C44Mab-18-mG2a) and investigated the antitumor efficacy against CD44v3–10 and oral SCC (OSCC) xenografts by comparing anti-pan-CD44 mAb, C44Mab-46-mG2a.

2. Results

2.1. Flow Cytometric Analysis against CHO/CD44v3–10, HSC-2, and SAS Cells Using C44Mab-18-mG2a and C44Mab-46-mG2a

We previously established an anti-CD44v10 mAb (C44Mab-18, IgM, kappa) and showed the availability for flow cytometry, western blotting, and immunohistochemistry against OSCC tissues [38]. In the present study, we cloned the VH cDNA of C44Mab-18 and combined it with the CH cDNA of mouse IgG2a. We also cloned the VL cDNA of C44Mab-18 and combined it with the CL cDNA of the mouse kappa light chain. Finally, a class-switched C44Mab-18 (C44Mab-18-mG2a) was produced (Figure 1A). We also used mouse IgG2a-type C44Mab-46 (C44Mab-46-mG2a) as an anti-pan CD44 mAb [40]. In reduced conditions, we confirm the purity of original and recombinant mAbs by SDS-PAGE (Supplementary Figure S1). We next confirmed the reactivity of C44Mab-18-mG2a and C44Mab-46-mG2a using CHO/CD44v3–10 and CD44s cells. Both C44Mab-18-mG2a and C44Mab-46-mG2a detected CHO/CD44v3–10 cells in a concentration-dependent manner (Figure 1B). The reactivity of C44Mab-18-mG2a to CHO/CD44v3–10 was superior to that of C44Mab-46-mG2a (Figure 1B). In contrast, C44Mab-18-mG2a did not react with CHO/CD44s cells compared to C44Mab-46-mG2a (Figure 1C). Both C44Mab-18-mG2a and C44Mab-46-mG2a did not respond with CHO-K1 cells (Supplementary Figure S2). These results confirmed that C44Mab-18-mG2a recognizes only CHO/CD44v3–10 and that C44Mab-46-mG2a recognizes both CHO/CD44v3–10 and CHO/CD44s.
We next investigated the reactivity of C44Mab-18-mG2a and C44Mab-46-mG2a against endogenous CD44-expressing OSCC cell lines, HSC-2 and SAS. Both C44Mab-18-mG2a and C44Mab-46-mG2a reacted with HSC-2 (Figure 2A) and SAS (Figure 2B) cells in a concentration-dependent manner. The reactivity of C44Mab-18-mG2a to these cells was superior to that of C44Mab-46-mG2a (Figure 2). We also used PMab-231 as a control mouse IgG2a, which did not react with CHO/CD44v3–10, HSC-2, and SAS cells (Supplementary Figure S3).

2.2. Induction of ADCC and CDC by C44Mab-18-mG2a and C44Mab-46-mG2a against CHO/CD44v3–10 Cells

Next, we performed in vitro ADCC and CDC assays to examine the cytotoxicity of C44Mab-18-mG2a and C44Mab-46-mG2a against CHO/CD44v3–10 cells. As shown in Figure 3A, C44Mab-18-mG2a significantly exerted ADCC against CHO/CD44v3–10 cells in the presence of mouse splenocytes (30% cytotoxicity, p < 0.01) compared with control mouse IgG2a (PMab-231, 11% cytotoxicity). Although a tendency of increased ADCC compared with the control was observed by C44Mab-46-mG2a, the difference was not significant.
In contrast, C44Mab-46-mG2a significantly exerted CDC against CHO/CD44v3–10 cells in the presence of complements (27% cytotoxicity, p < 0.05) compared with the control (12% cytotoxicity). We did not observe a significant difference in CDC between C44Mab-18-mG2a and the control (Figure 3B)
These results indicated that C44Mab-18-mG2a and C44Mab-46-mG2a possess different properties for exerting ADCC and CDC against CHO/CD44v3–10 cells.

2.3. Antitumor Effects of C44Mab-18-mG2a and C44Mab-46-mG2 in the Mouse Xenografts of CHO/CD44v3–10

We next evaluated the in vivo antitumor effect of C44Mab-18-mG2a and C44Mab-46-mG2a against CHO/CD44v3–10 xenograft tumors inoculated in nude mice. C44Mab-18-mG2a, C44Mab-46-mG2a, or control mouse IgG2a (100 µg/mouse) were intraperitoneally injected into mice on days 7, 14, and 21, following the inoculation. The tumor volume was measured on days 7, 14, 17, 21, 24, and 28. The C44Mab-18-mG2a and C44Mab-46-mG2a administration resulted in a significant reduction in tumor volume on days 17 (p < 0.05 in C44Mab-18-mG2a), 21 (p < 0.01), 24 (p < 0.01), and 28 (p < 0.01) compared with that of the control mouse IgG2a (Figure 4A). The C44Mab-18-mG2a and C44Mab-46-mG2a administration resulted in 56% and 50% reductions in tumor volume compared with the control mouse IgG2a on day 28, respectively.
The weight of CHO/CD44v3–10 tumors treated with C44Mab-18-mG2a was significantly lower than those treated with the control mouse IgG2a (Figure 4B,C, 62% reduction; p < 0.05). Although a 53% reduction in tumor weight was observed by C44Mab-46-mG2a treatment, it is not statistically different compared to the control (p = 0.0626). The loss of body weight was not observed in the CHO/CD44v3–10 tumor-implanted mice during the treatments (Figure 4D,E).

2.4. Induction of ADCC and CDC by C44Mab-18-mG2a and C44Mab-46-mG2a against HSC-2 and SAS Cells

Next, we performed in vitro ADCC and CDC assays to examine the cytotoxicity of C44Mab-18-mG2a and C44Mab-46-mG2a against HSC-2 and SAS cells. Both C44Mab-18-mG2a and C44Mab-46-mG2a significantly exerted ADCC against HSC-2 cells [Figure 5A, 17% (p < 0.01) and 13% (p < 0.05) cytotoxicity, respectively] and SAS cells [Figure 5C, 19% (p < 0.01) and 14% (p < 0.05) cytotoxicity, respectively] compared with the control.
Both C44Mab-18-mG2a and C44Mab-46-mG2a significantly exerted CDC against HSC-2 cells [Figure 5B, 27% (p < 0.05) and 40% (p < 0.01) cytotoxicity, respectively] compared with the control. In SAS cells, C44Mab-46-mG2a significantly exerted CDC [Figure 5D, 26% (p < 0.05) cytotoxicity] compared with the control. We could not observe the significant difference of CDC against SAS cells between C44Mab-18-mG2a and the control (Figure 5D).

2.5. Antitumor Effects of C44Mab-18-mG2a and C44Mab-46-mG2 in the Mouse Xenografts of HSC-2 and SAS

In the HSC-2 and SAS xenograft models, C44Mab-18-mG2a, C44Mab-46-mG2a, or control mouse IgG2a (500 µg/mouse) were intraperitoneally administrated into mice on days 7 and 14, following the inoculation. The tumor volume was measured on days 7, 14, and 17. The C44Mab-18-mG2a and C44Mab-46-mG2a administration resulted in a significant reduction in both tumor volume on day 14 (p < 0.01) and day 17 (p < 0.01) compared with that of the control mouse IgG2a (Figure 6A,B). The C44Mab-18-mG2a and C44Mab-46-mG2a administration resulted in 43% and 36% reduction of HSC-2 tumor volume, respectively compared with that treated with the control mouse IgG2a on day 17. The C44Mab-18-mG2a and C44Mab-46-mG2a administration also resulted in a 33% and 32% reduction of SAS tumor volume, respectively, compared with that treated with the control mouse IgG2a on day 17.
The weight of HSC-2 tumors treated with C44Mab-18-mG2a and C44Mab-46-mG2a was significantly lower than that treated with the control mouse IgG2a [Figure 6C, 40% (p < 0.01) and 30% (p < 0.05) reduction, respectively]. The weight of SAS tumors treated with C44Mab-18-mG2a and C44Mab-46-mG2a was significantly lower than that treated with the control mouse IgG2a [Figure 6D, 23% (p < 0.01) and 19% (p < 0.05) reduction, respectively]. The loss of body weight was not observed in the HSC-2 and SAS tumor-implanted mice during the treatments (Figure 6E,F).

3. Discussion

Among CD44v, v10-containing isoforms include the most abundant CD44v, such as CD44v3–10, CD44v6–10, and CD44v8–10 [1,41]. Therefore, anti-CD44v10 mAbs including C44Mab-18-mG2a can target the broad range of CD44v-expressing tumor cells. In this study, we evaluated the antitumor activities against CD44-positive cells compared with an anti-pan-CD44 mAb, C44Mab-46-mG2a. C44Mab-18-mG2a exhibited the higher reactivity to CHO/CD44v3–10 and OSCC cells compared with C44Mab-46-mG2a (Figure 1 and Figure 2). C44Mab-18-mG2a exhibited a superior ADCC against CD44v3–10 (Figure 3) and OSCC (Figure 5) cells. In contrast, C44Mab-46-mG2a showed a superior CDC against those cells. Furthermore, C44Mab-18-mG2a or C44Mab-46-mG2a similarly inhibited CD44v3–10 and OSCC xenograft growth compared with the control mouse IgG2a (Figure 4 and Figure 6). These results indicate that C44Mab-18-mG2a could be a promising therapeutic regimen for CD44v10-positive tumors.
In CHO/CD44v3–10 cells, C44Mab-18-mG2a and C44Mab-46-mG2a recognized common target, but mainly exerted ADCC and CDC activity, respectively (Figure 3). The epitope of C44Mab-46 was previously determined as 174-TDDDV-178 sequence in the constant exon 5-encoded region [30] which is relatively apart from transmembrane domain compared to variant exon 10-encoded region recognized by C44Mab-18 [38]. To activate the classical pathway of complement, an ordered hexamer formation of IgG mAb is required to bind to the hexavalent complement C1q [42,43]. The structure of C44Mab-46-mG2a–CD44v3–10 complex may provide the appropriate space to form the hexameric structure of mAb–C1q complex and recruit the pore-forming membrane attack complex to exert CDC. In contrast, C44Mab-18-mG2a showed a higher reactivity to CHO/CD44v3–10 compared with C44Mab-46-mG2a in flow cytometry (Figure 1). The difference of the reactivity and the epitope would influence the ADCC activity. Further studies are required to reveal the relationship among the affinity of mAb, epitope, and ADCC activity
Near-infrared photoimmunotherapy (NIR-PIT) uses a targeted mAb conjugated with a photoactivatable dye such as IRDye700DX (IR700) [44]. When the mAb binds to the antigen-expressed target cells, IR700 induces plasma membrane rupture and immunogenic cell death by NIR-light exposure. Preclinical studies of anti-pan-CD44 mAb-based NIR-PIT (IM7-IR700) were conducted. In the syngeneic mouse model of OSCC, IM7-IR700 administration and the NIR light exposure to OSCC tumors resulted in a significant reduction but failed to induce durable antitumor responses [45]. Because IM7 is a pan-CD44 mAb, IM7 might target not only tumor cells, but also CD44s-positive immune cells which involve in the antitumor immunity. The expression of CD44v is low in hematopoietic cells compared with CD44s [1]. We previously showed that C44Mab-18 can distinguish tumor cells from stromal tissues in immunohistochemistry. In contrast, C44Mab-46 stained both tumor and stromal tissue including fibroblasts and leukocytes [38]. Therefore, anti-CD44v10 mAb such as C44Mab-18 might be a promising mAb for NIR-PIT without affecting the host immune cells in the tumor microenvironment.
Since both CD44s and CD44v are expressed in normal cells, there is a concern of adverse effects due to the recognition of normal cells by mAbs. In fact, clinical trials of the anti-CD44v6 mAb–ADC to advanced solid tumors were discontinued because of the skin toxicities [13,18]. Therefore, cancer specific mAbs (CasMabs) are desired to reduce the adverse effects. A CasMab against CD44v6 (clone 4C8) recognizes aberrantly O-glycosylated Tn (GalNAcα1-O-Ser/Thr) antigen in variant exon 6-encoded region. The 4C8 mAb was further developed to chimeric antigen receptor (CAR)-T cells, which exhibited target-specific in vitro cytotoxicity and significant tumor regression in vivo [46]. We have developed CasMabs against various tumor antigens, including HER2 (clones H2Mab-214 [47] and H2Mab-250 [48]) and reported the antitumor effect in mouse xenograft models using recombinant mouse IgG2a or human IgG1 mAbs [49,50]. These anti-HER2 mAbs were screened by the reactivity to cancer and normal cells in flow cytometry. H2Mab-214 was revealed to recognize a locally misfolded structure in the Cys-rich HER2 extracellular domain 4, which usually forms a β-sheet [47]. H2Mab-250 also shows a specific reactivity against HER2-positive tumor cells, which has been developed as CAR-T cell therapy. The phase I study has been conducted in the US (NCT06241456). We have developed CasMabs against CD44s or CD44v by comparing the reactivity against tumor and normal cells. The anti-CD44 CasMabs could contribute to developing novel modalities such as ADCs and CAR-T cells.

4. Materials and Methods

4.1. Cell Lines and Cell Culture

CHO-K1 was obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). OSCC cell lines, HSC-2 and SAS were obtained from the Japanese Collection of Research Bioresources (Osaka, Japan). CHO/CD44s and CHO/CD44v3–10 were previously established by transfecting pCAG-Ble/PA16-CD44s and pCAG-Ble/PA16-CD44v3–10 into CHO-K1 cells using a Neon transfection system (Thermo Fisher Scientific, Inc., Waltham, MA, USA) [29,38].
HSC-2 and SAS was cultured in Dulbecco’s Modified Eagle Medium (DMEM, Nacalai Tesque, Inc.) containing 10% (v/v) heat−inactivated fetal bovine serum (FBS, Thermo Fisher Scientific Inc.), 100 U/mL of penicillin (Nacalai Tesque, Inc.), 100 μg/mL streptomycin (Nacalai Tesque, Inc.), and 0.25 μg/mL amphotericin B (Nacalai Tesque, Inc.).
CHO/CD44v3–10 was cultured in Roswell Park Memorial Institute (RPMI)-1640 medium (Nacalai Tesque, Inc.) supplemented with 10% (v/v) FBS, antibiotics as mentioned above, and 5 mg/mL Zeocin (InvivoGen, San Diego, CA, USA). All cells were grown in a humidified incubator at 37°C with 5% CO2.

4.2. Antibodies

An anti-pan-CD44 mAb (C44Mab-46) and an anti-CD44v10 mAb (C44Mab-18) were previously established [29,38]. A recombinant mouse IgG2a-type mAb, C44Mab-46-mG2a, was generated previously [40]. To generate a recombinant mouse IgG2a-type mAb from C44Mab-18 (IgM, kappa), VH cDNAs of C44Mab-18 and CH of mouse IgG2a were cloned into the pCAG-Ble vector (FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan). VL and mouse kappa light chain (CL) cDNA of C44Mab-18 was also cloned into the pCAG-Neo vector (FUJIFILM Wako Pure Chemical Corporation). Using the ExpiCHO Expression System (Thermo Fisher Scientific, Inc), the vectors were transfected into BINDS-09 cells (http://www.med-tohoku-antibody.com/topics/001_paper_cell.htm) [51] and the supernatants were collected. C44Mab-18-mG2a were purified using Ab-Capcher (ProteNova Co., Ltd., Kagawa, Japan). PMab-231 (a control mouse IgG2a) was previously described [49].

4.3. Flow Cytometry

CHO/CD44v3–10, HSC-2, and SAS were obtained using 1 mM ethylenediamine tetraacetic acid (EDTA; Nacalai Tesque, Inc.) and 0.25% trypsin treatment. The cells were treated with C44Mab-18-mG2a, C44Mab-46-mG2a, PMab-231, or blocking buffer [0.1% bovine serum albumin (BSA; Nacalai Tesque, Inc.) in phosphate-buffered saline (PBS)] (control) for 30 min at 4˚C. Subsequently, the cells were incubated in Alexa Fluor 488-conjugated anti-mouse IgG (1:2,000; Cell Signaling Technology, Inc., Danvers, MA, USA) for 30 min at 4˚C. Fluorescence data were collected using the SA3800 Cell Analyzer (Sony Corp., Tokyo, Japan) and analyzed using SA3800 software ver. 2.05 (Sony Corp.).

4.4. ADCC

The ADCC activity of C44Mab-18-mG2a and C44Mab-46-mG2a was measured as follows. The target cells (CHO/CD44v3–10, HSC-2, and SAS) were labeled with 10 µg/mL Calcein AM (Thermo Fisher Scientific, Inc.) and plated in 96-well plates (1 × 104 cells/well). The calcein-labeled target cells were mixed with the effector splenocyte (effector to target ratio, 100:1) from female BALB/c nude mice (Jackson Laboratory Japan, Inc., Kanagawa, Japan) with 100 μg/ml of C44Mab-18-mG2a, C44Mab-46-mG2a, or control mouse IgG2a (PMab-231). After a 4.5-hour incubation at 37°C, the calcein release into the medium was measured using a microplate reader (Power Scan HT; BioTek Instruments, Inc., Winooski, VT).
The cytolyticity (% lysis) was determined: % lysis is calculated as (E - S)/(M - S) x 100, where “E” indicates the fluorescence in effector and target cell cultures, “S” means the spontaneous fluorescence of only target cells, and “M” indicates the maximum fluorescence after treatment with a lysis buffer [10 mM Tris-HCl (pH 7.4), 10 mM EDTA, and 0.5% Triton X-100]. Statistical analyses were performed using GraphPad PRISM 6 software (GraphPad Software, Inc., La Jolla, CA, USA). All data are shown as mean ± standard error of the mean (SEM). One-way ANOVA with Tukey's multiple comparisons test was used for the statistical analyses. p < 0.05 was considered to indicate a statistically significant difference.

4.5. CDC

The calcein-labeled target cells were mixed with rabbit complement (final dilution 1:10, Low-Tox-M Rabbit Complement; Cedarlane Laboratories, Hornby, ON, Canada) and 100 μg/ml of C44Mab-18-mG2a, C44Mab-46-mG2a, or control mouse IgG2a (PMab-231). After a 4-hour incubation at 37°C, the calcein release into the medium was measured. Statistical analyses were performed as described above.

4.6. Antitumor Activity of C44Mab-18-mG2a and C44Mab-46-mG2a in Xenografts of CHO/CD44v3–10, HSC-2, and SAS

The animal study protocol was approved (approval nos. 2024-013 and 2024-038) by the Institutional Committee for Experiments of the Institute of Microbial Chemistry (Numazu, Japan). CHO/CD44v3–10, HSC-2, or SAS cells (5 × 106 cells) suspended with BD Matrigel Matrix Growth Factor Reduced (BD Biosciences, Franklin Lakes, NJ, USA) were inoculated into the left flank of female BALB/c nude mice subcutaneously. On day 7 after the inoculation, 100 μg of C44Mab-18-mG2a (n=8), C44Mab-46-mG2a (n=8), or control mouse IgG2a (PMab-231) (n=8) in 100 μl PBS were injected intraperitoneally. Additional antibody injections were performed on days 14 and 21. The tumor volume was measured on the indicated days.
In the HSC-2, or SAS xenograft experiment, 500 μg of C44Mab-18-mG2a (n=8), C44Mab-46-mG2a (n=8), or control mouse IgG2a (PMab-231) (n=8) in 100 μl PBS were injected intraperitoneally on days 7 and 14 after the inoculation. The tumor volume was measured on the indicated days. The xenograft tumors were carefully removed from the sacrificed mice and weighed immediately.
All data are expressed as the mean ± standard error of the mean (SEM). In tumor weight measurement, one-way ANOVA with Tukey's multiple comparisons test was conducted. Two-way ANOVA with Tukey's multiple comparisons test was utilized for tumor volume and mice weight. GraphPad Prism 6 (GraphPad Software, Inc.) was used for all calculations. p < 0.05 was considered to indicate a statistically significant difference.

Supplementary Materials

The following supporting information can be downloaded at the website of this paper posted on Preprints.org, Figure S1: Confirmation of the purified mAbs.; Figure S2: Flow cytometry using C44Mab-18-mG2a and C44Mab-46-mG2a against CHO-K1 cells; Figure S3: Flow cytometry using control mouse IgG2a (PMab-231) against CHO/CD44v3–10, HSC-2 and SAS cells.

Author Contributions

For research articles with several authors, a short paragraph specifying their individual contributions must be provided. The following statements should be used “Conceptualization, M.K., M.K.K., and Y.Kato; methodology, T.O.; formal analysis, T.T.; investigation, K.I., H.S., T.O., G.L., and T.T.; data curation, H.S. and Y.Kato; writing—original draft preparation, K.I. and H.S.; writing—review and editing, Y.Kato; supervision, A.O. and Y.Katori; project administration, Y.Kato.; funding acquisition, H.S., T.T., M.K.K., and Y.Kato. All authors have read and agreed to the published version of the manuscript.”

Funding

This research was supported in part by the Japan Agency for Medical Research and Development (AMED) under Grant Numbers 24am0521010 (to Y.Kato), JP23ama121008 (to Y.Kato), JP23am0401013 (to Y.Kato), JP23bm1123027 (to Y.Kato), and JP23ck0106730 (to Y.Kato), and by the Japan Society for the Promotion of Science (JSPS) Grants-in-Aid for Scientific Research (KAKENHI) grant nos. 22K06995 (to H.S.), 21K20789 (to T.T.), 21K07168 (to M.K.K.), and 22K07224 (to Y.Kato).

Institutional Review Board Statement

The Institutional Committee for Experiments of the Institute of Microbial Chemistry approved animal experiments (approval nos. 2024-013 and 2024-038).

Informed Consent Statement

Not applicable.

Data Availability Statement

The data presented in this study are available in the article and supplementary material.

Acknowledgments

The authors thank Shun-ichi Ohba and Akiko Harakawa (Institute of Microbial Chemistry [BIKAKEN], Numazu, the Microbial Chemistry Research Foundation) for technical assistance with animal experiments.

Conflicts of Interest

The authors have no conflicts of interest to declare.

References

  1. Ponta, H.; Sherman, L.; Herrlich, P.A. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003, 4, 33–45. [Google Scholar] [CrossRef] [PubMed]
  2. Zöller, M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer 2011, 11, 254–267. [Google Scholar] [CrossRef] [PubMed]
  3. Prochazka, L.; Tesarik, R.; Turanek, J. Regulation of alternative splicing of CD44 in cancer. Cell Signal 2014, 26, 2234–2239. [Google Scholar] [CrossRef] [PubMed]
  4. Guo, Q.; Yang, C.; Gao, F. The state of CD44 activation in cancer progression and therapeutic targeting. Febs j 2021. [Google Scholar] [CrossRef] [PubMed]
  5. Zöller, M. CD44, Hyaluronan, the Hematopoietic Stem Cell, and Leukemia-Initiating Cells. Front Immunol 2015, 6, 235. [Google Scholar] [CrossRef] [PubMed]
  6. Jackson, D.G.; Bell, J.I.; Dickinson, R.; Timans, J.; Shields, J.; Whittle, N. Proteoglycan forms of the lymphocyte homing receptor CD44 are alternatively spliced variants containing the v3 exon. J Cell Biol 1995, 128, 673–685. [Google Scholar] [CrossRef] [PubMed]
  7. Bennett, K.L.; Jackson, D.G.; Simon, J.C.; Tanczos, E.; Peach, R.; Modrell, B.; Stamenkovic, I.; Plowman, G.; Aruffo, A. CD44 isoforms containing exon V3 are responsible for the presentation of heparin-binding growth factor. J Cell Biol 1995, 128, 687–698. [Google Scholar] [CrossRef] [PubMed]
  8. Matzke, A.; Sargsyan, V.; Holtmann, B.; Aramuni, G.; Asan, E.; Sendtner, M.; Pace, G.; Howells, N.; Zhang, W.; Ponta, H.; et al. Haploinsufficiency of c-Met in cd44-/- mice identifies a collaboration of CD44 and c-Met in vivo. Mol Cell Biol 2007, 27, 8797–8806. [Google Scholar] [CrossRef] [PubMed]
  9. Orian-Rousseau, V.; Chen, L.; Sleeman, J.P.; Herrlich, P.; Ponta, H. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev 2002, 16, 3074–3086. [Google Scholar] [CrossRef]
  10. Ishimoto, T.; Nagano, O.; Yae, T.; Tamada, M.; Motohara, T.; Oshima, H.; Oshima, M.; Ikeda, T.; Asaba, R.; Yagi, H.; et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell 2011, 19, 387–400. [Google Scholar] [CrossRef]
  11. Wada, F.; Koga, H.; Akiba, J.; Niizeki, T.; Iwamoto, H.; Ikezono, Y.; Nakamura, T.; Abe, M.; Masuda, A.; Sakaue, T.; et al. High expression of CD44v9 and xCT in chemoresistant hepatocellular carcinoma: Potential targets by sulfasalazine. Cancer Sci 2018, 109, 2801–2810. [Google Scholar] [CrossRef]
  12. Birzele, F.; Voss, E.; Nopora, A.; Honold, K.; Heil, F.; Lohmann, S.; Verheul, H.; Le Tourneau, C.; Delord, J.P.; van Herpen, C.; et al. CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients. Clin Cancer Res 2015, 21, 2753–2762. [Google Scholar] [CrossRef]
  13. Tijink, B.M.; Buter, J.; de Bree, R.; Giaccone, G.; Lang, M.S.; Staab, A.; Leemans, C.R.; van Dongen, G.A. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res 2006, 12, 6064–6072. [Google Scholar] [CrossRef]
  14. Zhang, S.; Wu, C.C.; Fecteau, J.F.; Cui, B.; Chen, L.; Zhang, L.; Wu, R.; Rassenti, L.; Lao, F.; Weigand, S.; et al. Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44. Proc Natl Acad Sci U S A 2013, 110, 6127–6132. [Google Scholar] [CrossRef]
  15. Vey, N.; Delaunay, J.; Martinelli, G.; Fiedler, W.; Raffoux, E.; Prebet, T.; Gomez-Roca, C.; Papayannidis, C.; Kebenko, M.; Paschka, P.; et al. Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia. Oncotarget 2016, 7, 32532–32542. [Google Scholar] [CrossRef]
  16. Menke-van der Houven van Oordt, C.W.; Gomez-Roca, C.; van Herpen, C.; Coveler, A.L.; Mahalingam, D.; Verheul, H.M.; van der Graaf, W.T.; Christen, R.; Rüttinger, D.; Weigand, S.; et al. First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors. Oncotarget 2016, 7, 80046–80058. [Google Scholar] [CrossRef]
  17. Verel, I.; Heider, K.H.; Siegmund, M.; Ostermann, E.; Patzelt, E.; Sproll, M.; Snow, G.B.; Adolf, G.R.; van Dongen, G.A. Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearing head-and-neck cancer xenografts. Int J Cancer 2002, 99, 396–402. [Google Scholar] [CrossRef]
  18. Riechelmann, H.; Sauter, A.; Golze, W.; Hanft, G.; Schroen, C.; Hoermann, K.; Erhardt, T.; Gronau, S. Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. Oral Oncol 2008, 44, 823–829. [Google Scholar] [CrossRef]
  19. Tsao, L.C.; Force, J.; Hartman, Z.C. Mechanisms of Therapeutic Antitumor Monoclonal Antibodies. Cancer Res 2021, 81, 4641–4651. [Google Scholar] [CrossRef]
  20. Reis, E.S.; Mastellos, D.C.; Ricklin, D.; Mantovani, A.; Lambris, J.D. Complement in cancer: untangling an intricate relationship. Nat Rev Immunol 2018, 18, 5–18. [Google Scholar] [CrossRef]
  21. Taylor, R.P.; Lindorfer, M.A. Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies. Semin Immunol 2016, 28, 309–316. [Google Scholar] [CrossRef] [PubMed]
  22. Reff, M.E.; Carner, K.; Chambers, K.S.; Chinn, P.C.; Leonard, J.E.; Raab, R.; Newman, R.A.; Hanna, N.; Anderson, D.R. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994, 83, 435–445. [Google Scholar] [CrossRef] [PubMed]
  23. de Weers, M.; Tai, Y.T.; van der Veer, M.S.; Bakker, J.M.; Vink, T.; Jacobs, D.C.; Oomen, L.A.; Peipp, M.; Valerius, T.; Slootstra, J.W.; et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 2011, 186, 1840–1848. [Google Scholar] [CrossRef] [PubMed]
  24. Zent, C.S.; Secreto, C.R.; LaPlant, B.R.; Bone, N.D.; Call, T.G.; Shanafelt, T.D.; Jelinek, D.F.; Tschumper, R.C.; Kay, N.E. Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab. Leuk Res 2008, 32, 1849–1856. [Google Scholar] [CrossRef] [PubMed]
  25. Schmudde, I.; Laumonnier, Y.; Köhl, J. Anaphylatoxins coordinate innate and adaptive immune responses in allergic asthma. Semin Immunol 2013, 25, 2–11. [Google Scholar] [CrossRef] [PubMed]
  26. Carroll, M.C.; Isenman, D.E. Regulation of humoral immunity by complement. Immunity 2012, 37, 199–207. [Google Scholar] [CrossRef] [PubMed]
  27. Weisser, N.E.; Sanches, M.; Escobar-Cabrera, E.; O'Toole, J.; Whalen, E.; Chan, P.W.Y.; Wickman, G.; Abraham, L.; Choi, K.; Harbourne, B.; et al. An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity. Nat Commun 2023, 14, 1394. [Google Scholar] [CrossRef] [PubMed]
  28. Yamada, S.; Itai, S.; Nakamura, T.; Yanaka, M.; Kaneko, M.K.; Kato, Y. Detection of high CD44 expression in oral cancers using the novel monoclonal antibody, C(44)Mab-5. Biochem Biophys Rep 2018, 14, 64–68. [Google Scholar] [CrossRef] [PubMed]
  29. Goto, N.; Suzuki, H.; Tanaka, T.; Asano, T.; Kaneko, M.K.; Kato, Y. Development of a Novel Anti-CD44 Monoclonal Antibody for Multiple Applications against Esophageal Squamous Cell Carcinomas. Int J Mol Sci 2022, 23. [Google Scholar] [CrossRef]
  30. Takei, J.; Asano, T.; Suzuki, H.; Kaneko, M.K.; Kato, Y. Epitope Mapping of the Anti-CD44 Monoclonal Antibody (C44Mab-46) Using Alanine-Scanning Mutagenesis and Surface Plasmon Resonance. Monoclon Antib Immunodiagn Immunother 2021, 40, 219–226. [Google Scholar] [CrossRef]
  31. Asano, T.; Kaneko, M.K.; Takei, J.; Tateyama, N.; Kato, Y. Epitope Mapping of the Anti-CD44 Monoclonal Antibody (C44Mab-46) Using the REMAP Method. Monoclon Antib Immunodiagn Immunother 2021, 40, 156–161. [Google Scholar] [CrossRef]
  32. Asano, T.; Kaneko, M.K.; Kato, Y. Development of a Novel Epitope Mapping System: RIEDL Insertion for Epitope Mapping Method. Monoclon Antib Immunodiagn Immunother 2021, 40, 162–167. [Google Scholar] [CrossRef] [PubMed]
  33. Suzuki, H.; Kitamura, K.; Goto, N.; Ishikawa, K.; Ouchida, T.; Tanaka, T.; Kaneko, M.K.; Kato, Y. A Novel Anti-CD44 Variant 3 Monoclonal Antibody C(44)Mab-6 Was Established for Multiple Applications. Int J Mol Sci 2023, 24. [Google Scholar] [CrossRef] [PubMed]
  34. Kudo, Y.; Suzuki, H.; Tanaka, T.; Kaneko, M.K.; Kato, Y. Development of a Novel Anti-CD44 variant 5 Monoclonal Antibody C44Mab-3 for Multiple Applications against Pancreatic Carcinomas. Antibodies 2023, 12, 31. [Google Scholar] [CrossRef] [PubMed]
  35. Ejima, R.; Suzuki, H.; Tanaka, T.; Asano, T.; Kaneko, M.K.; Kato, Y. Development of a Novel Anti-CD44 Variant 6 Monoclonal Antibody C(44)Mab-9 for Multiple Applications against Colorectal Carcinomas. Int J Mol Sci 2023, 24. [Google Scholar] [CrossRef]
  36. Suzuki, H.; Ozawa, K.; Tanaka, T.; Kaneko, M.K.; Kato, Y. Development of a Novel Anti-CD44 Variant 7/8 Monoclonal Antibody, C44Mab-34, for Multiple Applications against Oral Carcinomas. Biomedicines 2023, 11, 1099. [Google Scholar] [CrossRef] [PubMed]
  37. Tawara, M.; Suzuki, H.; Goto, N.; Tanaka, T.; Kaneko, M.K.; Kato, Y. A Novel Anti-CD44 Variant 9 Monoclonal Antibody C44Mab-1 was Developed for Immunohistochemical Analyses Against Colorectal Cancers Curr. Issues Mol. Biol. 2023, 45, 3658–3673. [Google Scholar] [CrossRef] [PubMed]
  38. Ishikawa, K.; Suzuki, H.; Kaneko, M.K.; Kato, Y. Establishment of a Novel Anti-CD44 Variant 10 Monoclonal Antibody C(44)Mab-18 for Immunohistochemical Analysis against Oral Squamous Cell Carcinomas. Curr Issues Mol Biol 2023, 45, 5248–5262. [Google Scholar] [CrossRef] [PubMed]
  39. Suzuki, H.; Tanaka, T.; Goto, N.; Kaneko, M.K.; Kato, Y. Development of a Novel Anti-CD44 Variant 4 Monoclonal Antibody C44Mab-108 for Immunohistochemistry. Curr Issues Mol Biol 2023, 45, 1875–1888. [Google Scholar] [CrossRef]
  40. Ishikawa, K.; Suzuki, H.; Ohishi, T.; Nakamura, T.; Yanaka, M.; Li, G.; Tanaka, T.; Ohkoshi, A.; Kawada, M.; Kaneko, M.K.; et al. Antitumor activities of anti-CD44 monoclonal antibodies in mouse xenograft models of esophageal cancer. Oncology Reports in press. 2024. [Google Scholar]
  41. Zhang, H.; Brown, R.L.; Wei, Y.; Zhao, P.; Liu, S.; Liu, X.; Deng, Y.; Hu, X.; Zhang, J.; Gao, X.D.; et al. CD44 splice isoform switching determines breast cancer stem cell state. Genes Dev 2019, 33, 166–179. [Google Scholar] [CrossRef]
  42. Hiemstra, I.H.; Santegoets, K.C.M.; Janmaat, M.L.; De Goeij, B.; Ten Hagen, W.; van Dooremalen, S.; Boross, P.; van den Brakel, J.; Bosgra, S.; Andringa, G.; et al. Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity. EBioMedicine 2023, 93, 104663. [Google Scholar] [CrossRef]
  43. de Jong, R.N.; Beurskens, F.J.; Verploegen, S.; Strumane, K.; van Kampen, M.D.; Voorhorst, M.; Horstman, W.; Engelberts, P.J.; Oostindie, S.C.; Wang, G.; et al. A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface. PLoS Biol 2016, 14, e1002344. [Google Scholar] [CrossRef]
  44. Mitsunaga, M.; Ogawa, M.; Kosaka, N.; Rosenblum, L.T.; Choyke, P.L.; Kobayashi, H. Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat Med 2011, 17, 1685–1691. [Google Scholar] [CrossRef] [PubMed]
  45. Nagaya, T.; Nakamura, Y.; Okuyama, S.; Ogata, F.; Maruoka, Y.; Choyke, P.L.; Allen, C.; Kobayashi, H. Syngeneic Mouse Models of Oral Cancer Are Effectively Targeted by Anti-CD44-Based NIR-PIT. Mol Cancer Res 2017, 15, 1667–1677. [Google Scholar] [CrossRef]
  46. Aasted, M.K.M.; Groen, A.C.; Keane, J.T.; Dabelsteen, S.; Tan, E.; Schnabel, J.; Liu, F.; Lewis, H.S.; Theodoropulos, C.; Posey, A.D.; et al. Targeting Solid Cancers with a Cancer-Specific Monoclonal Antibody to Surface Expressed Aberrantly O-glycosylated Proteins. Mol Cancer Ther 2023, 22, 1204–1214. [Google Scholar] [CrossRef]
  47. Arimori, T.; Mihara, E.; Suzuki, H.; Ohishi, T.; Tanaka, T.; Kaneko, M.K.; Takagi, J.; Kato, Y. Locally misfolded HER2 expressed on cancer cells is a promising target for development of cancer-specific antibodies. Structure 2024. [Google Scholar] [CrossRef]
  48. Kaneko, M.K.; Suzuki, H.; Kato, Y. Establishment of a Novel Cancer-specific Anti-HER2 Monoclonal Antibody H2Mab-250/H2CasMab-2 for breast cancers. Monoclon Antib Immunodiagn Immunother 2024, in press. [Google Scholar] [CrossRef]
  49. Kaneko, M.K.; Suzuki, H.; Ohishi, T.; Nakamura, T.; Tanaka, T.; Kato, Y. A Cancer-Specific Monoclonal Antibody against HER2 Exerts Antitumor Activities in Human Breast Cancer Xenograft Models. Int J Mol Sci 2024, 25. [Google Scholar] [CrossRef]
  50. Suzuki, H.; Ohishi, T.; Tanaka, T.; Kaneko, M.K.; Kato, Y. Anti-HER2 cancer-specific mAb, H2Mab-250-hG1 possesses higher complement-dependent cytotoxicity than trastuzumab. Int. J. Mol. Sci. 2024, 25. [Google Scholar] [CrossRef]
  51. Li, G.; Suzuki, H.; Ohishi, T.; Asano, T.; Tanaka, T.; Yanaka, M.; Nakamura, T.; Yoshikawa, T.; Kawada, M.; Kaneko, M.K.; et al. Antitumor activities of a defucosylated anti-EpCAM monoclonal antibody in colorectal carcinoma xenograft models. Int J Mol Med 2023, 51. [Google Scholar] [CrossRef] [PubMed]
Preprints 114163 g001
Figure 1. Flow cytometry using C44Mab-18-mG2a and C44Mab-46-mG2a. (A) Class-switched mouse IgG2a mAbs, C44Mab-18-mG2a, and C44Mab-46-mG2a were generated from C44Mab-18 (mouse IgM) and C44Mab-46 (mouse IgG1), respectively. CHO/CD44v3–10 (B) and CHO/CD44s (C) cells were treated with buffer control (black) or 10-0.01 µg/mL of C44Mab-18-mG2a and C44Mab-46-mG2a (red). The cells were further treated with Alexa Fluor 488-conjugated anti-mouse IgG. Fluorescence data were analyzed using the SA3800 Cell Analyzer.
Figure 1. Flow cytometry using C44Mab-18-mG2a and C44Mab-46-mG2a. (A) Class-switched mouse IgG2a mAbs, C44Mab-18-mG2a, and C44Mab-46-mG2a were generated from C44Mab-18 (mouse IgM) and C44Mab-46 (mouse IgG1), respectively. CHO/CD44v3–10 (B) and CHO/CD44s (C) cells were treated with buffer control (black) or 10-0.01 µg/mL of C44Mab-18-mG2a and C44Mab-46-mG2a (red). The cells were further treated with Alexa Fluor 488-conjugated anti-mouse IgG. Fluorescence data were analyzed using the SA3800 Cell Analyzer.
Preprints 114163 g001
Preprints 114163 g002
Figure 2. Flow cytometry using C44Mab-18-mG2a and C44Mab-46-mG2a against oral squamous cell carcinoma (OSCC) cell lines. HSC-2 (A) and SAS (B) cells were treated with buffer control (black) or 10-0.01 µg/mL of C44Mab-18-mG2a and C44Mab-46-mG2a (red). The cells were further treated with Alexa Fluor 488-conjugated anti-mouse IgG. Fluorescence data were analyzed using the SA3800 Cell Analyzer.
Figure 2. Flow cytometry using C44Mab-18-mG2a and C44Mab-46-mG2a against oral squamous cell carcinoma (OSCC) cell lines. HSC-2 (A) and SAS (B) cells were treated with buffer control (black) or 10-0.01 µg/mL of C44Mab-18-mG2a and C44Mab-46-mG2a (red). The cells were further treated with Alexa Fluor 488-conjugated anti-mouse IgG. Fluorescence data were analyzed using the SA3800 Cell Analyzer.
Preprints 114163 g002
Preprints 114163 g003
Figure 3. Evaluation of ADCC and CDC activity of C44Mab-18-mG2a and C44Mab-46-mG2a against CHO/CD44v3–10 cells. The ADCC (A) and CDC (B) induced by C44Mab-18-mG2a, C44Mab-46-mG2a, or control mouse IgG2a (mIgG2a, PMab-231) against CHO/CD44v3–10 cells. Values are shown as mean ± SEM. Asterisks indicate statistical significance (**p < 0.01 and *p < 0.05; one-way ANOVA with Tukey's multiple comparisons test).
Figure 3. Evaluation of ADCC and CDC activity of C44Mab-18-mG2a and C44Mab-46-mG2a against CHO/CD44v3–10 cells. The ADCC (A) and CDC (B) induced by C44Mab-18-mG2a, C44Mab-46-mG2a, or control mouse IgG2a (mIgG2a, PMab-231) against CHO/CD44v3–10 cells. Values are shown as mean ± SEM. Asterisks indicate statistical significance (**p < 0.01 and *p < 0.05; one-way ANOVA with Tukey's multiple comparisons test).
Preprints 114163 g003
Preprints 114163 g004
Figure 4. Antitumor activity of C44Mab-18-mG2a and C44Mab-46-mG2a against CHO/CD44v3–10 xenograft. (A) Tumor volume of CHO/CD44v3–10 xenograft. CHO/CD44v3–10 cells (5 × 106 cells) were injected into mice subcutaneously. On days 7, 14, and 21, 100 μg of C44Mab-18-mG2a (n=8), C44Mab-46-mG2a (n=8) or control mouse IgG2a (mIgG2a, PMab-231) (n=8) were injected into mice intraperitoneally (arrows). The tumor volume was measured on days 7, 14, 17, 21, 24, and 28 following the inoculation. Values are presented as the mean ± SEM. *p < 0.05 and **p < 0.01 (two-way ANOVA with Tukey's multiple comparisons test). The weight (B) and appearance (C) of excised CHO/CD44v3–10 xenografts on day 28. Values are presented as the mean ± SEM. *p < 0.05 (one-way ANOVA with Tukey's multiple comparisons test). The body weight (D) and appearance (E) of CHO/CD44v3–10 xenograft-bearing mice treated with C44Mab-18-mG2a, C44Mab-46-mG2a, or control mIgG2a. Scale bar, 1 cm.
Figure 4. Antitumor activity of C44Mab-18-mG2a and C44Mab-46-mG2a against CHO/CD44v3–10 xenograft. (A) Tumor volume of CHO/CD44v3–10 xenograft. CHO/CD44v3–10 cells (5 × 106 cells) were injected into mice subcutaneously. On days 7, 14, and 21, 100 μg of C44Mab-18-mG2a (n=8), C44Mab-46-mG2a (n=8) or control mouse IgG2a (mIgG2a, PMab-231) (n=8) were injected into mice intraperitoneally (arrows). The tumor volume was measured on days 7, 14, 17, 21, 24, and 28 following the inoculation. Values are presented as the mean ± SEM. *p < 0.05 and **p < 0.01 (two-way ANOVA with Tukey's multiple comparisons test). The weight (B) and appearance (C) of excised CHO/CD44v3–10 xenografts on day 28. Values are presented as the mean ± SEM. *p < 0.05 (one-way ANOVA with Tukey's multiple comparisons test). The body weight (D) and appearance (E) of CHO/CD44v3–10 xenograft-bearing mice treated with C44Mab-18-mG2a, C44Mab-46-mG2a, or control mIgG2a. Scale bar, 1 cm.
Preprints 114163 g004
Preprints 114163 g005
Figure 5. Evaluation of ADCC and CDC activity of C44Mab-18-mG2a and C44Mab-46-mG2a against HSC-2 and SAS cells. The ADCC (A,C) and CDC (B,D) induced by C44Mab-18-mG2a, C44Mab-46-mG2a, or control mouse IgG2a (mIgG2a, PMab-231) against HSC-2 (A,B) and SAS (C,D) cells. Values are shown as mean ± SEM. Asterisks indicate statistical significance (**p < 0.01 and *p < 0.05; one-way ANOVA with Tukey's multiple comparisons test).
Figure 5. Evaluation of ADCC and CDC activity of C44Mab-18-mG2a and C44Mab-46-mG2a against HSC-2 and SAS cells. The ADCC (A,C) and CDC (B,D) induced by C44Mab-18-mG2a, C44Mab-46-mG2a, or control mouse IgG2a (mIgG2a, PMab-231) against HSC-2 (A,B) and SAS (C,D) cells. Values are shown as mean ± SEM. Asterisks indicate statistical significance (**p < 0.01 and *p < 0.05; one-way ANOVA with Tukey's multiple comparisons test).
Preprints 114163 g005
Preprints 114163 g006
Figure 6. Antitumor activity of C44Mab-18-mG2a and C44Mab-46-mG2a against HSC-2 and SAS xenograft. (A,B) Tumor volume in HSC-2 (A) and SAS (B) xenograft. HSC-2 and SAS cells (5 × 106 cells) were injected into mice subcutaneously. On days 7 and 14, 500 μg of C44Mab-18-mG2a (n=8), C44Mab-46-mG2a (n=8), or control mouse IgG2a (mIgG2a, PMab-231) (n=8) were injected into mice intraperitoneally (arrows). The tumor volume was measured on days 7, 14, and 17 following the inoculation. Values are presented as the mean ± SEM. **p < 0.01 (two-way ANOVA with Tukey's multiple comparisons test). (C,D) The weight and appearance of the excised HSC-2 (C) and SAS (D) xenografts on day 17. Values are presented as the mean ± SEM. * P < 0.05 and **p < 0.01 (one-way ANOVA with Tukey's multiple comparisons test). (E,F) The body weight of HSC-2 (E) and SAS (F) xenograft-bearing mice treated with C44Mab-18-mG2a, C44Mab-46-mG2a, or control mIgG2a. Scale bar, 1 cm.
Figure 6. Antitumor activity of C44Mab-18-mG2a and C44Mab-46-mG2a against HSC-2 and SAS xenograft. (A,B) Tumor volume in HSC-2 (A) and SAS (B) xenograft. HSC-2 and SAS cells (5 × 106 cells) were injected into mice subcutaneously. On days 7 and 14, 500 μg of C44Mab-18-mG2a (n=8), C44Mab-46-mG2a (n=8), or control mouse IgG2a (mIgG2a, PMab-231) (n=8) were injected into mice intraperitoneally (arrows). The tumor volume was measured on days 7, 14, and 17 following the inoculation. Values are presented as the mean ± SEM. **p < 0.01 (two-way ANOVA with Tukey's multiple comparisons test). (C,D) The weight and appearance of the excised HSC-2 (C) and SAS (D) xenografts on day 17. Values are presented as the mean ± SEM. * P < 0.05 and **p < 0.01 (one-way ANOVA with Tukey's multiple comparisons test). (E,F) The body weight of HSC-2 (E) and SAS (F) xenograft-bearing mice treated with C44Mab-18-mG2a, C44Mab-46-mG2a, or control mIgG2a. Scale bar, 1 cm.
Preprints 114163 g006
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
bsky
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

Privacy Settings

© 2025 MDPI (Basel, Switzerland) unless otherwise stated